Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 3, 2025

NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025

View original at finance.yahoo.com
NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025 NTT Research, NTT, Inc. and NTT DATA showcase foundational theory, system-level advances and enterprise-grade innovations across five major themes at premier AI conference News Highlights: NTT Research, NTT, Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI is becoming ubiquitous, but how these computational engines actually work remains—to a surprising degree—a mystery, which is why our scientists keep probing with fundamental questions

    80% confidence
  • Standard SAEs architectures embed implicit geometric assumptions that not only reveal concepts inside models but also shape what concepts can be discovered

    80% confidence
  • With the EU AI Act mandating watermarking, the topic has become increasingly urgent, and even state-of-the-art watermarking schemes can be reverse engineered, revealing significant risks for enterprises

    80% confidence
  • Researchers must keep pace with operational challenges in AI development

    80% confidence
  • Understanding training dynamics in in-context learning may enable engineering reliable ICL behavior

    80% confidence
  • The watermarking vulnerability findings expose a foundational vulnerability in today's AI trust and traceability mechanisms

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com